MedSpa revenues grew 90% year-over-year
Net income from discontinued operations of $9.99 million due to gain on sale of Canadian Primary Care and Licensee business
Mexico operations fully ceased as of June 30, 2025
TORONTO, July 12, 2025–(BUSINESS WIRE)–Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) (“Jack Nathan Health”, “JNH” or the “Company”) announced today its audited consolidated annual financial results for the fourth quarter of fiscal 2025, and fiscal year ended January 31, 2025. Jack Nathan Health’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
Disclosure Regarding Filing Timing
As previously disclosed in a press release issued on June 9, 2025, the Company was unable to file its annual financial statements, MD&A, and related CEO and CFO certifications for the fiscal year ended January 31, 2025, by the prescribed filing deadline of May 31, 2025. The delay was due to operational restructuring, resource realignment, and transition impacts following the divestiture of its Canadian primary care operations and the winding down of Mexico operations. The Company is pleased to confirm that it has now completed the filings within the 90-day permitted period, and all required documents are available on SEDAR+.
Management Commentary
Mike Marchelletta, Chief Executive Officer, commented:
“Fiscal 2025 was a pivotal year of transition for Jack Nathan Health. We successfully completed the divestiture of our Canadian primary care and licensee business, which significantly improved our balance sheet and eliminated legacy obligations. Following year-end, we also ceased all clinic operations in Mexico after the termination of our agreement with Walmart Mexico. With both legacy business segments now exited, our current focus is on internal restructuring, stabilizing our operations, and preserving cash while evaluating future strategic opportunities. We believe these actions have positioned the Company for a more focused path forward.”
Financial Highlights for the fiscal year ended January 31, 2025
Operating Results | |||||
2025 | 2024 | 2023 | |||
$ | $ | ||||
Revenues (Continuing + Discontinued) | 19,146,626 | 19,144,923 | 15,487,698 | ||
Net loss from continuing operations | (2,530,374) | (1,333,217) | (6,902,759) | ||
Net Income/(loss) from discontinued operations | 9,995,129 | (5,302,750) | – | ||
Total comprehensive income/ (loss) | 7,678,435 | (6,737,300) | (7,077,020) |
For the fiscal year ended January 31, 2025, total consolidated revenues were $19.1 million, consistent with the prior year. Revenues from continuing operations increased 26% to $8.7 million driven by the full-year contribution from MedSpa operations and the continued activity of the Mexico division through fiscal year-end. MedSpa revenues were $1.03 million, up 90% year-over-year. Discontinued operations contributed $10.4 million in revenue prior to the sale of the Canadian medical clinic…
Read More: Jack Nathan Health Announces Its Q4 and Year End Fiscal 2025 Financial
